consumption-total-did-46.html
DANMAP 2015 3D
47 / 144
47 danmap
2015
5. antimicrobial consumption
in humans 5.3 primary health care 5.3.1 total consumption in primary health care in 2015 the consumption in the primary sector at 16.46 did
was almost the same as in 2014, (16.40 did), (table 5.1 a and b).since 2006 the total consumption increased by 6% (15.45 did to 16.46 did). during the last 20 years the increase was 34%, showing gradual increases from 12.20 did in 1996 to the peak of 17.34 did in 2011 and lately reaching a plateau with the consumption of 2015 being close to that reported in 2009, (figure 5.1b). the trends in the consumption of leading antimicrobials for the last decade are shown in figure 5.2. beta-lactamase sensitive penicillins continued being the antimicrobial class with the highest consumption. they are the only antimicrobial class with an overall decreasing trend for the past deacde, decreas- ing from 5.40 did in 2006 to 4.33 in 2015, a decline of 19% . macrolides also show decreasing trends for the 10 year period, from 2.31 did in 2006 to 1.77 did in 2015, the decrease being interrupted from 2010 to the beginning of 2012 due to a doublem, nationwide mycoplasma pneumoniae epidemic. a new mycoplasma epidemic was registered in the autumn of 2015, lasting until the spring of 2016; this will most likely be reflected in the consumption patterns for 2016. most notable increases were shown for penicillins with extend- ed spectrum and combination penicillins; these increased from 2.95 to 3.61 did (22%) and from 0.12 to 1.42 did (1200%), respectively. such increases may reflect changes in treatment recommendations for specific infections; for the penicillins with extended spectrum the change is probably due to shifts in the treatment of urinary tract infections from sulfamethizole to pivmecillinam as the prime drug. this change caused the number of ddds to decrease from 4 g to 0.6 g per day, but simultaneously the duration of treatment increased. likewise the change from phenoxymethylpenicillin to amoxicillin with atc group (a) therapeutic group year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 j01aa tetracyclines 1.38 1.48 1.54 1.61 1.69 1.64 1.76 1.96 1.66 1.61 j01ca penicillins with extended spectrum 2.95 3.25 3.26 3.29 3.47 3.41 3.40 3.48 3.53 3.61 j01ce beta-lactamase sensitive penicillins 5.40 5.67 5.30 5.12 5.25 5.31 4.68 4.65 4.38 4.33 j01cf beta-lactamase resistant penicillins 1.05 1.09 1.12 1.13 1.17 1.14 1.21 1.30 1.36 1.38 j01cr combinations of penicillins, including beta- lactamase inhibitors 0.12 0.19 0.27 0.45 0.68 0.89 1.05 1.22 1.30 1.42 j01d cephalosporins and other ?-lactam antibiotics 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 j01ea trimethoprim and derivatives 0.47 0.49 0.49 0.48 0.51 0.50 0.52 0.53 0.55 0.56 j01eb short-acting sulfonamides 0.35 0.31 0.28 0.27 0.26 0.24 0.22 0.22 0.21 0.18 j01ee combinations of sulfonamides and trimethoprim, including derivatives 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.00 0.00 j01fa macrolides 2.31 2.42 2.28 2.21 2.44 2.47 2.19 1.93 1.79 1.77 j01ff lincosamides 0.02 0.02 0.03 0.03 0.04 0.04 0.04 0.05 0.05 0.05 j01gb aminoglycosides 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 j01ma fluoroquinolones 0.37 0.44 0.51 0.52 0.57 0.57 0.55 0.52 0.50 0.49 j01xa glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 j01xb polymyxins 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.02 0.02 j01xc steroid antibacterials (kombination fusidic acid) 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 j01xe nitrofuran derivatives (nitrofurantoin) 0.46 0.47 0.47 0.49 0.51 0.50 0.49 0.49 0.48 0.45 j01xx other antibacterials (methenamine >99%) 0.27 0.26 0.27 0.26 0.27 0.26 0.25 0.24 0.24 0.25 j01xd and p01ab* nitroimidazole derivatives (metronidazole) 0.22 0.23 0.24 0.27 0.28 0.28 0.28 0.28 0.28 0.28 j01+p01ab antibacterial agents for systemic use (total) 15.45 16.45 16.15 16.22 17.21 17.34 16.75 16.95 16.40 16.46 table 5.1b. consumption of antimicrobial agents for systemic use in primary health care (ddd/1000 inhabitant-days), denmark, 2006 - 2015 danmap 2015 a) from the 2015 edition of the anatomical therapeutic chemical (atc) classification system *) all metronidazole preparations, formerly only listed as j01xd, 10 years retrospective data included in the danmap report since 2014 fig 5.1b 0,00 5,00 10,00 15,00 20,00 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 defined daily doses/1000 inhabitant-days figure 5.1.b consumption in primary health care 1996 - 2015 consumption in primary health care 1996 - 2015 0 5 10 15 20 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 defined daily doses/1000 inhabitant - days figure 5.1b total antimicrobial consumption in primary health care 1996 - 2015, did consumption in primary health care 1996 - 2015 figure 5.1.b consumption in primary health care 1996 - 2015, did danmap 2015 fig 5.1b 0,00 5,00 10,00 15,00 20,00 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 defined daily doses/1000 inhabitant-days figure 5.1.b consumption in primary health care 1996 - 2015 consumption in primary health care 1996 - 2015 0 5 10 15 20 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 defined daily doses/1000 inhabitant - days figure 5.1b total antimicrobial consumption in primary health care 1996 - 2015, did consumption in primary health care 1996 - 2015
penicillins-2015-consumption-48.html
